Generic name fenofibrate capsules
English name fenofibrate capsules
Ingredients The main ingredient of this product is fenofibrate.
Properties This product is a capsule, and its contents are white or white-like crystalline powder.
Functional category
Pharmacology and Toxicology This product is a blood lipid regulator derived from clofibric acid, which can reduce blood low density lipoprotein, cholesterol and triglyceride by inhibiting the production of very low density lipoprotein and triglyceride and increasing their catabolism. It also increases the production of apolipoprotein A 1 and A 1 1, thus increasing high density lipoprotein. This product can also reduce the blood uric acid of normal people and patients with hyperuricemia. Animal experiments show that fenofibrate has teratogenic and carcinogenic effects.
Pharmacokinetics After oral administration, this product is well absorbed in gastrointestinal tract. Taking it with food can increase the absorption of fenofibrate. After oral administration, the plasma concentration reaches its peak in about 4-7 hours. The absorption half-life and elimination half-life after a single oral administration were 4.9 hours and 26.6 hours respectively, and the apparent distribution volume was 0.9 liter/kg. After continuous treatment, the half-life β is 2 1.7 hours. The binding rate of plasma protein was about 99%, and no accumulation was found after multi-dose administration. After absorption, it is mainly distributed in liver, kidney and intestine, followed by lung, heart and adrenal gland, and a small amount is distributed in testis, spleen and skin. Metabolism in liver and kidney tissues, after carboxyl reduction and glucuronidation, most metabolites are glucuronic acid products. After radioactive labeling, about 60% of metabolites are excreted by kidney and 25% by feces. The elimination half-life of this product is 20 hours, so it can be administered once a day. Studies have shown that the clearance rate of this product is obviously decreased in patients with severe renal insufficiency, and long-term medication can cause accumulation.
Indications This product is used to treat hyperlipidemia with unsatisfactory effect of adult diet control therapy, and its effect of reducing triglyceride and mixed hyperlipidemia is more obvious than cholesterol. However, this product can not completely replace diet control therapy, and can only be used as an auxiliary therapy on the basis of diet control.
Usage and dosage: Adults generally take 0. 1g capsules once, three times a day, and the maintenance dose is 0. 1g each time, 1-2 times a day. In order to reduce stomach discomfort, it can be taken with diet; Patients with renal insufficiency and elderly patients should reduce medication; After 2 months of treatment, no effect was observed.
The incidence of adverse reactions was about 2%- 15%. Gastrointestinal reactions including abdominal discomfort, diarrhea and constipation are the most common (about 5%); Rash (2%); Adverse reactions of nervous system include fatigue, headache, loss of libido, impotence, dizziness and insomnia (about 3%-4%); This product is a derivative of clofibric acid, which may cause myositis, myopathy and rhabdomyolysis syndrome, leading to the increase of serum creatine phosphokinase; Rhabdomyolysis occurs, mainly manifested as myalgia complicated with increased blood creatine phosphokinase, myoglobinuria and renal failure, but rare; Patients with nephrotic syndrome and other renal damage who lead to decreased serum albumin or hyperthyroidism have an increased risk of myopathy. (about1%); There is a tendency to increase gallstones, which can cause gallbladder diseases and even require surgery; At the initial stage of treatment, it can cause mild to moderate hematological changes, such as hemoglobin, hematocrit and leukopenia, and occasionally increase blood transaminase, including alanine and aspartate transaminase.
Fenofibrate allergic population taboo; Patients with gallbladder disease and cholelithiasis are prohibited. This product can increase the excretion of cholesterol to bile, thus causing gallstones. Patients with severe renal insufficiency, hepatic insufficiency, primary biliary cirrhosis or unexplained persistent liver dysfunction are prohibited.
Precautions: this product interferes with diagnosis, and platelet count, blood urea nitrogen, transaminase and blood calcium may increase after taking this product; Serum alkaline phosphatase, γ -glutamyltranspeptidase and bilirubin may decrease. Regular examination should be carried out during medication: ① whole blood picture and platelet count; ② Liver function examination; ③ Blood cholesterol, triglyceride or low density lipoprotein; ④ Blood creatine phosphokinase. If you have suspicious symptoms of myopathy (such as myalgia, tenderness, fatigue, etc. ) or serum creatine phosphokinase increased significantly, should stop taking drugs. While treating hyperlipidemia, we should also pay attention to and treat various primary diseases that can cause hyperlipidemia, such as hypothyroidism and diabetes. Some drugs can also cause hyperlipidemia, such as estrogen, thiazide diuretics and beta blockers. After drug withdrawal, there is no need for corresponding anti-hyperlipidemia treatment. Dietotherapy is always the primary method to treat hyperlipidemia, and exercise and weight loss will be superior to any form of drug treatment.
Pregnant women and lactating women are forbidden to take drugs. This product has no human experimental data.
At present, the efficacy and safety of this product for children have not been confirmed by experimental studies, so this product cannot be used for children.
The clearance rate of single dose of this product in elderly patients is similar to that in adults, but if there is renal insufficiency, the dose of this product should be reduced appropriately.
Drug interaction HMG-CoA reductase inhibitors, such as pravastatin, fluvastatin and simvastatin, should be used with caution, which may cause myalgia, rhabdomyolysis and serum creatine phosphokinase elevation. In severe cases, the drug should be stopped. When this product is combined with bile acid-binding resin (such as sphingosine), fenofibrate should be taken at least 1 hour or 4-6 hours before taking these drugs. Because bile acids can also be combined with other drugs taken at the same time, it will affect the absorption of other drugs. This product can enhance the curative effect of coumarin anticoagulants and prolong prothrombin time, so the dosage of oral anticoagulants should be reduced when combined, and then adjusted according to the test results. This product is mainly excreted through the kidney. When combined with immunosuppressants such as cyclosporine or other drugs with nephrotoxicity, it may lead to deterioration of renal function and should be reduced or stopped. When this product is combined with other drugs with high protein binding rate, it can increase its free form and enhance its curative effect, such as sulfonylurea hypoglycemic drugs such as tolbutamide, phenytoin and furosemide. The dosage of hypoglycemic drugs and other drugs should be adjusted when taking the above drugs during hypolipidemic treatment.
Excessive fenofibrate is highly bound to plasma protein, so when excessive fenofibrate occurs, systemic support treatment should be taken, regardless of hemodialysis.
standard
Storage, shading and sealed preservation.
Prescription or not
Investment information of fenofibrate capsules
More instructions on the use of fenofibrate capsules
Fenofibrate Capsule Manufacturer:
Fenofibrate Capsule Hubei Baike Hendi Pharmaceutical Co., Ltd. National Medicine Zhunzi H20045 138
Fenofibrate Capsule Modified Pharmaceutical Group Sichuan Pharmaceutical Co., Ltd. National Medicine Zhunzi H20045203
Fenofibrate Capsule Beijing Yimin Pharmaceutical Co., Ltd. National Medicine Zhunzi H11021115
Fenofibrate Capsule Beijing Jingfeng Pharmaceutical Co., Ltd. National Medicine Zhunzi H11021514
Fenofibrate Capsule Beijing Shuanghe Pharmaceutical Co., Ltd. National Medicine Zhunzi H 1 1020924
Fenofibrate Capsule North China Pharmaceutical Group Preparation Co., Ltd. National Medicine Zhunzi H 13020797
Fenofibrate Capsule Shijiazhuang Ou Yi Pharmaceutical Co., Ltd. National Medicine Zhunzi H 13022766
Fenofibrate Capsule Shenyang Dongling Pharmaceutical Co., Ltd. National Medicine Zhunzi H2 102 1577
Fenofibrate Capsule Shanghai Huayuan Changfu Pharmaceutical Group Liaoning Pharmaceutical Co., Ltd. National Medicine Zhunzi H2 102 1006
Fenofibrate Capsule Weikang Pharmaceutical Group Shenyang Yanfeng Pharmaceutical Co., Ltd. National Medicine Zhunzi H2 102 1546
Fenofibrate Capsules Chaoyang Fuxiang Pharmaceutical Co., Ltd. National Medicine Zhunzi H2 10245 14
Fenofibrate Capsule Jiangsu Chenpai Pharmaceutical Co., Ltd. National Medicine Zhunzi H3202 1950
Fenofibrate Capsule Jiangsu Hua En Pharmaceutical Group Co., Ltd. National Medicine Zhunzi H32022970
Fenofibrate Capsule Suzhou No.3 Pharmaceutical Factory Co., Ltd. National Medicine Zhunzi H32022758
Fenofibrate Capsule Fujian Lifeike Pharmaceutical Co., Ltd. National Medicine Zhunzi H35020589
Fenofibrate Capsules Lu Kang Chen Xin Pharmaceutical Co., Ltd. National Medicine Zhunzi H3702 18 19
Fenofibrate Capsule Qingdao Huanghai Pharmaceutical Co., Ltd. National Medicine Zhunzi H37022235
Fenofibrate Capsule Shandong Lu Hua Pharmaceutical Co., Ltd. National Medicine Zhunzi H37022 10 1
Fenofibrate Capsule Shanghai Xinyi Wanxiang Pharmaceutical Co., Ltd. National Medicine Zhunzi H3 1020386
Fenofibrate capsule national medicine standard H32024 139, state-owned Zhangjiagang Pharmaceutical Factory.
Fenofibrate Capsule Shanghai Xinya Pharmaceutical Minhang Co., Ltd. National Medicine Zhunzi H3 1022833
Fenofibrate Capsule Guangxi Bang Qi Pharmaceutical Co., Ltd. National Medicine Zhunzi H4502 1533
Fenofibrate Capsule Luohe Fang Hui Pharmaceutical Co., Ltd. National Medicine Zhunzi H4 102567 1
Fenofibrate Capsule Hunan Xiangyao Pharmaceutical Co., Ltd. National Medicine Zhunzi H43020845
Fenofibrate Capsule Guangzhou Maite Xinghua Pharmaceutical Factory Co., Ltd. National Medicine Zhunzi H44023828
Fenofibrate Capsule Wuhan No.4 Pharmaceutical Factory National Medicine Zhunzi H42020299
Fenofibrate Capsule Guangzhou Ou Hua Pharmaceutical Co., Ltd. National Medicine Zhunzi H44022634
Fenofibrate Capsule Luohe Nanjiecun Quanwei Pharmaceutical Co., Ltd. National Medicine Zhunzi H4 1023990
Fenofibrate Capsule Yichang Renfu Pharmaceutical Co., Ltd. National Medicine Zhunzi H4202205 1
Fenofibrate Capsule Guangzhou Dongkang Pharmaceutical Co., Ltd. National Medicine Zhunzi H44023505
Fenofibrate Capsule Henan Tian Fang Pharmaceutical Co., Ltd. National Medicine Zhunzi H4 1020959
Fenofibrate Capsules Xi 'an No.4 Pharmaceutical Factory National Medicine Zhunzi H6 102 1072
Fenofibrate Capsule Shaanxi Kangzheng Pharmaceutical Chemical Co., Ltd. National Medicine Zhunzi H20057323
Fenofibrate Capsule Shanghai Edefa Pharmaceutical Co., Ltd. National Medicine Zhunzi H20059 148
Fenofibrate Capsule Henan Tailong Pharmaceutical Co., Ltd. Yuzhong Pharmaceutical Factory National Medicine Zhunzi H2006343 1